A prostatectomy is surgery to partially or completely remove the prostate gland to treat conditions such as prostate cancer or benign prostatic hyperplasia (BPH). A radical prostatectomy is the ...

The most common surgery for prostate cancer is a radical prostatectomy. This surgery involves taking out the entire prostate gland, some lymph nodes and other nearby tissue, like the seminal vesicles ...

The probability of surgical success with telesurgery for radical prostatectomy and partial nephrectomy for small renal masses was non-inferior to local robotic surgery in a small randomized trial. The ...

Stereotactic body radiotherapy as salvage therapy after radical prostatectomy was well tolerated. Toxic effects were comparable to a historical cohort of patients receiving conventionally fractionated ...

CHICAGO — Men with high-risk localized or locally advanced prostate cancer who received apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy were significantly ...

Surgery reduced the risk of cancer death among men with de novo oligometastatic prostate cancer receiving systemic therapy. The addition of radical prostatectomy (RP) to best initial systemic therapy ...

Radical prostatectomy does not ensure a cure, with one in three men experiencing cancer recurrence and elevated PSA levels within 10 years post-surgery. Significant side effects of prostate removal ...

The precise identification of tumor boundaries during radical prostatectomy remains a major clinical challenge. As positive surgical margins occur in 15–40% of prostate cancer cases, the risk of ...

Obesity in itself is not a contraindication to radical prostatectomy, but it remains a risk factor for poor overall survival. Although obesity increases the technical complexity of radical ...

SamanTree Medical's Histolog® Scanner technology is featured in 13 peer-reviewed clinical papers in a special issue of BJU International.

Evaluation of the safety and efficacy of daily oral Angelica gigas Nakai (AGN)-INM176 in prostate cancer patients with rising plasma PSA (phase I/II trial). This is an ASCO Meeting Abstract from the ...